360 related articles for article (PubMed ID: 15370821)
1. Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.
Fiegl M; Schlemmer M; Wendtner CM; Abdel-Rahman S; Fahn W; Issels RD
Int J Hyperthermia; 2004 Sep; 20(6):661-70. PubMed ID: 15370821
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study.
Issels RD; Prenninger SW; Nagele A; Boehm E; Sauer H; Jauch KW; Denecke H; Berger H; Peter K; Wilmanns W
J Clin Oncol; 1990 Nov; 8(11):1818-29. PubMed ID: 2121910
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study.
Issels RD; Bosse D; Abdel-Rahman S; Starck M; Panzer M; Jauch KW; Stiegler H; Berger H; Sauer H; Peter K
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S233-7. PubMed ID: 8453705
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
7. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Loss JF; Santos PP; Leone LD; Brunetto AL
Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
9. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
10. A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma.
Westermann AM; Wiedemann GJ; Jager E; Jager D; Katschinski DM; Knuth A; Vörde Sive Vörding PZ; Van Dijk JD; Finet J; Neumann A; Longo W; Bakhshandeh A; Tiggelaar CL; Gillis W; Bailey H; Peters SO; Robins HI;
Oncology; 2003; 64(4):312-21. PubMed ID: 12759526
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
12. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
13. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
14. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
16. Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
De Pas T; Rosati G; Spitaleri G; Boni C; Tucci A; Frustaci S; Scalamogna R; Radice D; Boselli S; Toffalorio F; Catania C; Noberasco C; Delmonte A; Vecchio F; de Braud F
Chemotherapy; 2011; 57(3):217-24. PubMed ID: 21597285
[TBL] [Abstract][Full Text] [Related]
17. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia].
Wiedemann GJ; Robins HI; Katschinski DM; Mentzel M; van Heek R; Touhidi RR; Bucsky P; Gillis W; Feyerabend T; d'Oleire F; Freund C; Eleftheriadis S; Weiss C; Wagner T
Med Klin (Munich); 1996 May; 91(5):279-83. PubMed ID: 8709905
[No Abstract] [Full Text] [Related]
19. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
Kushner BH; Modak S; Kramer K; Basu EM; Roberts SS; Cheung NK
Cancer; 2013 Feb; 119(3):665-71. PubMed ID: 22951749
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]